142 related articles for article (PubMed ID: 2016615)
21. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
22. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
23. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant BCG immunotherapy for malignant melanoma.
Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
[TBL] [Abstract][Full Text] [Related]
26. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
Shibata HR; Jerry LM; Lewis MG; Mansell PW; Capek A; Marquis G
Ann N Y Acad Sci; 1976; 277(00):355-66. PubMed ID: 1069555
[No Abstract] [Full Text] [Related]
28. BCG, levamisole and transfer factor in the treatment of cancer.
Spitler LE
Prog Exp Tumor Res; 1980; 25():178-92. PubMed ID: 6986631
[No Abstract] [Full Text] [Related]
29. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
[TBL] [Abstract][Full Text] [Related]
30. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Peter HH; Deutschmann EM; Schultheis W; Deicher H
Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
32. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma.
Loutfi A; Shakr A; Jerry M; Hanley J; Shibata HR
Clin Invest Med; 1987 Jul; 10(4):325-8. PubMed ID: 3308241
[TBL] [Abstract][Full Text] [Related]
33. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
Storm FK; Sparks FC; Morton DL
Surg Gynecol Obstet; 1979 Jul; 149(1):17-21. PubMed ID: 451822
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant bacillus Calmette-Guérin therapy in non-Hodgkin's malignant lymphomas: long-term results of a randomized trial in a single institution.
Ravaud A; Eghbali H; Trojani M; Hoerni-Simon G; Soubeyran P; Hoerni B
J Clin Oncol; 1990 Apr; 8(4):608-14. PubMed ID: 2179478
[TBL] [Abstract][Full Text] [Related]
35. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.
Creagan ET; Dalton RJ; Ahmann DL; Jung SH; Morton RF; Langdon RM; Kugler J; Rodrigue LJ
J Clin Oncol; 1995 Nov; 13(11):2776-83. PubMed ID: 7595738
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
37. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.
Hortobagyi GN; Yap HY; Blumenschein GR; Gutterman JU; Buzdar AU; Tashima CK; Hersh EM
Cancer Treat Rep; 1978 Nov; 62(11):1685-92. PubMed ID: 728894
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
